Glaxosmithkline Share News (GSK)

Deutsche Bank upgrades GSK to 'buy'

(Sharecast News) - Analysts at Deutsche Bank upgraded biopharmaceutical firm GSK from 'hold' to 'buy' on Friday as they updated estimates and made changes to their net present value assumptions.

LONDON BROKER RATINGS: UBS likes LSEG; BofA lifts Weir Group

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

LONDON BRIEFING: Emis takeover and BT Openreach get watchdog scrutiny

(Alliance News) - London's FTSE 100 is called to open higher on Friday, ending a tumultuous week in the green.

How GSK plans to replenish its depleted medicine cabinet

GSK has overhauled R&D dept since Walmsley became CEO

*

GSK lauds trial findings; asthma drug backed for review in China

(Alliance News) - GSK PLC said on Tuesday its asthma drug was accepted for review in China, while it also reported a trial for a drug to treat an infectious disease met its primary endpoint.

GSK upbeat on meningitis vaccine candidate, asthma treatment

(Sharecast News) - Pharmaceutical giant GSK reported positive results from a phase three trial evaluating its MenABCWY combination vaccine candidate for meningitis on Tuesday.

SVB shock could have chilling effect on British biotech sector

UK deal averted disaster for biotech start-ups

*

SVB shock could have chilling effect on British biotech sector

UK deal averted disaster for biotech start-ups

*

GSK expects US launch of RSV vaccine with no supply issues

LONDON, March 9 (Reuters) - GSK expects to launch its respiratory syncytial virus (RSV) vaccine in the U.S. this year without supply constraints and sees China as a major future market for the shot, a senior executive told Reuters.

GSK set for US launch of RSV vaccine with no supply issues

LONDON, March 9 (Reuters) - GSK is prepared to launch its respiratory syncytial virus (RSV) vaccine in the U.S. this year without supply constraints and sees China as a major future market for the shot, the company’s head of vaccines research & development told Reuters.

Sareum says GSK's Sierra returns clinical study reports to CRT Pioneer

(Alliance News) - Sareum Holdings PLC on Monday said that GSK PLC subsidiary Sierra Oncology Inc has completed the return of the clinical study reports relating to SRA737 to Sarerum's co-development partner CRT Pioneer Fund LP.

TOP NEWS: Haleon revenue up; records loss due to GSK demerger costs

(Alliance News) - Haleon PLC on Thursday said revenue was up, as it declares its inaugural dividend following its GSK split.

GSK spinoff Haleon has no deals on immediate horizon

LONDON, March 2 (Reuters) - Consumer healthcare group Haleon's Chief Executive Brian McNamara said on Thursday he does not expect to announce any acquisitions or divestments imminently, amid analyst concerns its 2023 cost forecasts could hit consensus profit estimates.

LONDON BROKER RATINGS: Numis cuts BT to 'sell'; Citigroup cuts Babcock

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

LONDON MARKET OPEN: CRH shares jump as it plans US primary listing

(Alliance News) - Stock prices in London were lower early Thursday, with the FTSE 100 index being spared from a steeper fall thanks to a jump in CRH shares and a weaker pound.